JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

MeSH: lisurid-aplikace a dávkování

7 záznamů v PubMed Filtry

Článek

Management of restless legs syndrome by the partial D2-agonist terguride

Sleep medicine. 2003 Sep ; 4 (5) : 455-7.

Sleep Med
ISSN 1389-9457
Zdroj

BACKGROUND: Terguride as a partial D2-receptors agonist seems suitable for treatment of restless legs syndrome (RLS). METHODS: Nine RLS patients without previous dopaminergic therapy received a daily dose of terguride (0.25 mg) 29.9+/-16.9 (SD) days. RESULTS: Two patients enrolled in the study failed to turn up for a successive check up. The seven subjects who were re-examined complied with the therapy. Their RLS symptoms improved (as measured on the International RLS intensity scale), decreasing from 24.3+/-5.3 to 14+/-4.7 (p=0.014). However, the terguride treatment did not significantly alter the daytime sleepiness or the subjective duration of nocturnal sleep. The daily dose was doubled in three patients who reported insufficient RLS improvement. One of the three patients later reported augmentation.

MeSH
agonisté dopaminu aplikace a dávkování terapeutické užití MeSH
dospělí MeSH
lidé středního věku MeSH
lidé MeSH
lisurid aplikace a dávkování analogy a deriváty terapeutické užití MeSH
receptory dopaminu D2 agonisté MeSH
sebezhodnocení (psychologie) MeSH
senioři MeSH
spánek MeSH
stadia spánku účinky léků MeSH
syndrom neklidných nohou farmakoterapie patofyziologie MeSH
výsledek terapie MeSH
Check Tag
dospělí MeSH
lidé středního věku MeSH
lidé MeSH
mužské pohlaví MeSH
senioři MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
klinické zkoušky MeSH
Názvy látek
agonisté dopaminu MeSH
dironyl MeSH Prohlížeč
lisurid MeSH
receptory dopaminu D2 MeSH

Článek

Zástava laktace po potratu ve II. Trimestru jednorázovým podáním cabergolinu ve srovnání s desetidenním podáváním terguridu
[Arrest of lactation after 2nd trimester abortion with a single dose of cabergoline in comparison with 10-day administration of teguride]

Ceska gynekologie. 2003 Jan ; 68 (1) : 46-50.

Ceska Gynekol
ISSN 1210-7832
Zdroj

OBJECTIVE: The objective of the work was to compare the effectiveness and tolerance of a single administration of 1 mg cabergoline and 10-day administration of 1.5 mg terguride divided into three doses after 8-hour intervals, in the indication of arrest of lactation after an abortion during the second trimester. TYPE OF STUDY: Prospective clinical study. NAME AND PLACE OF DEPARTMENT: Gynaecological and Obstetric Clinic. First Medical Faculty Charles University and General Faculty Hospital Prague, Apolinárská 18, Prague 2. METHOD: During the period between January and October 2000 to 41 patients after abortion induced during the 2nd trimester terguride, 0.5 mg after 8-hour intervals, was administered for a 10-day period. During the subsequent period from November 2000 to September 2001 to 43 patients cabergoline was administered in a single dose within 12 hours after the abortion. During hospitalization the patients were asked daily for their subjective evaluation of the effect of treatment (vertigo, palpitations, headache, nausea, vomiting, abdominal pain, sleepiness, secretion from the breast, tension in the breasts) and the doctor evaluated the success of treatment objectively. Within 21 days after the abortion the patients were addressed over the phone on subjective and objective effects of treatment. For statistical evaluation Fisher's exact bilateral test was used. RESULTS: The "cabergoline" group displayed, as compared with the "terguride" group, significantly fewer undesirable effects (p < 0.01). No significant difference was found between groups (p = 0.1) as regards the necessity to repeat administration of the drug. None of the undesirable effects were so serious to call for interruption of treatment. CONCLUSION: Arrest of lactation during the second trimester of gestation is an integral part of care of the patient. Symptoms associated with lactation are adversely accepted by the patient. The incidence of undesirable effects after a single dose of cabergoline is significantly lower as compared with 10-day administration of terguride. A single dose of cabergoline during hospitalization improves the patients' compliance and thus the effect of treatment. Cabergoline can be used as the drug of first choice for arrest of lactation after abortion during the second trimester of pregnancy.

MeSH
dospělí MeSH
druhý trimestr těhotenství MeSH
ergoliny aplikace a dávkování MeSH
indukovaný potrat * MeSH
kabergolin MeSH
laktace účinky léků MeSH
lidé MeSH
lisurid aplikace a dávkování analogy a deriváty MeSH
mladiství MeSH
prospektivní studie MeSH
rozvrh dávkování léků MeSH
těhotenství MeSH
Check Tag
dospělí MeSH
lidé MeSH
mladiství MeSH
těhotenství MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
klinické zkoušky MeSH
srovnávací studie MeSH
Názvy látek
dironyl MeSH Prohlížeč
ergoliny MeSH
kabergolin MeSH
lisurid MeSH

Článek

Kombinovaná lécba akromegalie kombinací lanreotidu s terguridem
[Combined therapy of acromegaly with a combination of lanreotide and terguride]

Casopis lekaru ceskych. 2000 Nov 08 ; 139 (22) : 690-2.

Cas Lek Cesk
ISSN 0008-7335
Zdroj

BACKGROUND: The aim of the treatment of acromegaly is to normalise the hormonal activity. Besides the surgical and radiation treatment, medical therapy can be used. The project was set to determine the value of combined therapy with lanreotide and terguride in patients with active acromegaly. METHODS AND RESULTS: Nine patients previously treated with lanreotide for at least one year without normalisation of hormonal activity were included in the study. Terguride was added to lanreotide for one month. The combined treatment brought about reduction of growth hormone (GH) levels, however, with marginal significance only. GH-BP, IGF-I and IGFBP-3 serum levels were not changed significantly. Considering the individual cases, the combined treatment resulted in normalisation of GH levels in one patient and that of IGF-I in another one. Substantial decrease of GH levels (> 50%) was found in three patients and that of IGF-I (> 20%) in another one patient. CONCLUSIONS: The combined treatment of acromegaly appears to be more effective than monotherapy with lanreotide only in a subset of acromegalic patients.